PharmaSat
From Wikipedia, the free encyclopedia
PharmaSat was a nanosatellite developed by NASA Ames Research Center which measured the influence of microgravity upon yeast resistance to an antifungal agent. As a follow on to the GeneSat-1 mission, the Ames Small Spacecraft Division conducted the PharmaSat mission in collaboration with industry and local universities.[4]
Quick Facts Mission type, Operator ...
Mission type | Biological research |
---|---|
Operator | NASA |
COSPAR ID | 2009-028B |
SATCAT no. | 35002 |
Website | PharmaSat |
Mission duration | 6 months (planned) |
Spacecraft properties | |
Bus | 3U CubeSat |
Manufacturer | NASA Ames Space Center |
Launch mass | 4.5 kg (9.9 lb) |
Power | Solar cells and batteries |
Start of mission | |
Launch date | 19 May 2009, 23:55 UTC[1][2] |
Rocket | Minotaur I |
Launch site | MARS, Pad 0B |
Contractor | Orbital Sciences |
End of mission | |
Decay date | 14 August 2012 |
Orbital parameters | |
Reference system | Geocentric orbit[3] |
Regime | Low Earth orbit |
Perigee altitude | 428 km (266 mi) |
Apogee altitude | 466 km (290 mi) |
Inclination | 40.4° |
Period | 93.52 minutes |
Close
PharmaSat was the first nanosatellite to implement biological science guided by its Principal Investigator. The mission was designed to aid the development of medicines or techniques to enable long-term crewed space travel and habitation.